Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Dexamethasone

FDA-approved product (tablet, oral), marketed as Aeroseb-Dex, Decaderm, Decadron and 13 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Dexamethasone
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Acne
  • Adrenal gland disease
  • Adrenal gland hyperfunction
  • Allergic conjunctivitis
  • Allergic rhinitis
  • Ankylosing spondylitis
  • Aplastic anemia
  • Asthma
  • Atopic eczema
  • Autoimmune thrombocytopenic purpura
  • Bursitis
  • Cancer
  • Chorioretinitis
  • Choroiditis
  • Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency
  • Congenital adrenal hyperplasia
  • and 62 more

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Corticosteroids for local oral treatment; Corticosteroids; Corticosteroids, moderately potent (group ii); Corticosteroids, moderately potent, other combinations; Corticosteroids, combinations for treatment of acne
FDA pharmacologic class
Corticosteroid FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA53.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli32.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae30.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis25.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Dexamethasone in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.6 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.1 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

-6.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Dexamethasone with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)

    NCT02431208 · start 2015-07-22

    Registered record
    Registry ID
    NCT02431208
    Conditions
    Multiple Myeloma
    Interventions
    Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody; Daratumumab; Lenalidomide; Pomalidomide; Dexamethasone
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2015-07-22
    Completion
    2021-03-19
    Enrolment
    85

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Myeloma
    InterventionAtezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody; Daratumumab; Lenalidomide; Pomalidomide +1 more
    PhasePhase 1
    Registry statusCompleted

  • Efficacy and Toxicity Study of Pomalidomide and Dexamethasone in Patients Who Have Relapsed After Exposure to Lenalidomide and Bortezomib

    NCT02158702 · start 2014-11

    Registered record
    Registry ID
    NCT02158702
    Conditions
    Multiple Myeloma; Relapse After Use of Lenalidomide and Bortezomib
    Interventions
    Pomalidomide and Dexamethasone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2014-11
    Completion
    2018-11
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Myeloma; Relapse After Use of Lenalidomide and Bortezomib
    InterventionPomalidomide and Dexamethasone
    PhasePhase 2
    Registry statusUnknown

  • Study of the Efficacy and Safety of RsqVD Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma

    NCT02219178 · start 2014-11

    Registered record
    Registry ID
    NCT02219178
    Conditions
    Multiple Myeloma
    Interventions
    lenalidomide; Subcutaneous bortezomib; Dexamethasone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2014-11
    Completion
    2020-04
    Enrolment
    42

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Myeloma
    Interventionlenalidomide; Subcutaneous bortezomib; Dexamethasone
    PhasePhase 2
    Registry statusCompleted

  • Phase 1b Study Evaluating ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed-and-Refractory Multiple Myeloma

    NCT02189343 · start 2014-09-15

    Registered record
    Registry ID
    NCT02189343
    Conditions
    Multiple Myeloma
    Interventions
    ACY-1215 in combination with pomalidomide and dexamethasone
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2014-09-15
    Completion
    2018-04-30
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Myeloma
    InterventionACY-1215 in combination with pomalidomide and dexamethasone
    PhasePhase 1
    Registry statusCompleted

  • Pre-Emptive Analgesia in Ano-Rectal Surgery

    NCT02402543 · start 2014-06

    Registered record
    Registry ID
    NCT02402543
    Conditions
    Hemorrhoids; Fissure in Ano; Rectal Fistula; Anal Condyloma
    Interventions
    Gabapentin; Ketamine; Acetaminophen; Dexamethasone; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2014-06
    Completion
    2017-05
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHemorrhoids; Fissure in Ano; Rectal Fistula; Anal Condyloma
    InterventionGabapentin; Ketamine; Acetaminophen; Dexamethasone +1 more
    PhaseNot applicable
    Registry statusCompleted

  • Study of ACY-1215 in Combination With Lenalidomide, and Dexamethasone in Multiple Myeloma

    NCT01583283 · start 2012-07-12

    Registered record
    Registry ID
    NCT01583283
    Conditions
    Multiple Myeloma
    Interventions
    ACY-1215; lenalidomide; Dexamethasone
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2012-07-12
    Completion
    2021-03-24
    Enrolment
    38

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Myeloma
    InterventionACY-1215; lenalidomide; Dexamethasone
    PhasePhase 1
    Registry statusCompleted

  • Dexamethasone for Pain After Shoulder Surgery

    NCT01414569 · start 2011-11

    Registered record
    Registry ID
    NCT01414569
    Conditions
    Shoulder Impingement Syndrome; Arthritis
    Interventions
    Dexamethasone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2011-11
    Completion
    2013-06
    Enrolment
    97

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionShoulder Impingement Syndrome; Arthritis
    InterventionDexamethasone
    PhasePhase 4
    Registry statusCompleted

  • Incidence of Chemotherapy-Induced Nausea and Vomiting Associated With Docetaxel-Cyclophosphamide in Early Breast Cancer.

    NCT01298193 · start 2011-05

    Registered record
    Registry ID
    NCT01298193
    Conditions
    Breast Cancer
    Interventions
    Aprepitant
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2011-05
    Completion
    2014-04
    Enrolment
    212

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    InterventionAprepitant
    PhasePhase 4
    Registry statusCompleted

  • Phase II Study of TPA Plus Dexamethasone & CMT in Hematologic Malignancies

    NCT01009931 · start 2011-03

    Registered record
    Registry ID
    NCT01009931
    Conditions
    Leukemia
    Interventions
    12-O-tetradecanoylphorbol-13-acetate; Dexamethasone; Choline magnesium trisalicylate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2011-03
    Completion
    2014-09
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLeukemia
    Intervention12-O-tetradecanoylphorbol-13-acetate; Dexamethasone; Choline magnesium trisalicylate
    PhasePhase 2
    Registry statusTerminated

  • Treatment of Natural Killer/T Cell Lymphoma-Ⅲ/Ⅳ

    NCT01501149 · start 2011-01

    Registered record
    Registry ID
    NCT01501149
    Conditions
    Nasal and Nasal-type NK/T-cell Lymphoma
    Interventions
    DDGP(cisplatin,dexamethasone,gemcitabine,pegaspargase); Modified SMILE （MTX，DEX，IFO，L-ASP，Etoposide，Mesna）
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2011-01
    Completion
    2019-05
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNasal and Nasal-type NK/T-cell Lymphoma
    InterventionDDGP(cisplatin,dexamethasone,gemcitabine,pegaspargase); Modified SMILE （MTX，DEX，IFO，L-ASP，Etoposide，Mesna）
    PhasePhase 4
    Registry statusUnknown

  • Lenalidomide With or Without Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

    NCT00772915 · start 2008-12-03

    Registered record
    Registry ID
    NCT00772915
    Conditions
    Multiple Myeloma and Plasma Cell Neoplasm
    Interventions
    dexamethasone; lenalidomide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2008-12-03
    Completion
    2018-06-27
    Enrolment
    39

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Myeloma and Plasma Cell Neoplasm
    Interventiondexamethasone; lenalidomide
    PhasePhase 2
    Registry statusCompleted

  • Bortezomib and High-dose Melphalan at Myeloma Relapse

    NCT00508209 · start 2007-07

    Registered record
    Registry ID
    NCT00508209
    Conditions
    Multiple Myeloma
    Interventions
    bortezomib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2007-07
    Completion
    2010-09
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Myeloma
    Interventionbortezomib
    PhasePhase 2
    Registry statusUnknown

  • Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combined With Combination Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver

    NCT00492999 · start 2007-05

    Registered record
    Registry ID
    NCT00492999
    Conditions
    Colorectal Cancer; Metastatic Cancer
    Interventions
    dexamethasone; floxuridine; fluorouracil; irinotecan hydrochloride; leucovorin calcium; oxaliplatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2007-05
    Completion
    2027-05
    Enrolment
    64

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColorectal Cancer; Metastatic Cancer
    Interventiondexamethasone; floxuridine; fluorouracil; irinotecan hydrochloride +2 more
    PhasePhase 2
    Registry statusActive not recruiting

  • GEM05 for Patients With Multiple Myeloma Under 65 Years

    NCT00461747 · start 2006-03

    Registered record
    Registry ID
    NCT00461747
    Conditions
    Multiple Myeloma
    Interventions
    VBMCP/VBAD/Velcade; Thalidomide/Dexamethasone; Velcade/Thalidomide/Dexamethasone
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2006-03
    Completion
    2008-12
    Enrolment
    390

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Myeloma
    InterventionVBMCP/VBAD/Velcade; Thalidomide/Dexamethasone; Velcade/Thalidomide/Dexamethasone
    PhasePhase 3
    Registry statusCompleted

  • To Compare Intravitreal Clindamycin & Dexamethasone With Classic Treatment of Toxoplasmic Retinochoroiditis

    NCT00372294 · start 2005-07

    Registered record
    Registry ID
    NCT00372294
    Conditions
    Chorioretinitis
    Interventions
    pyrimethamine-sulfadiazine + prednisolone; Clindamycin+Dexamethasone
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2005-07
    Completion
    2008-11
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChorioretinitis
    Interventionpyrimethamine-sulfadiazine + prednisolone; Clindamycin+Dexamethasone
    PhasePhase 3
    Registry statusUnknown